Noxopharm advances autoimmune drug trial as HERACLES enters second phase

Australian clinical-stage biotechnology company Noxopharm (ASX:NOX) has commenced the second part of its HERACLES clinical trial, marking another milestone in the development of SOF-SKN, a novel topical therapy targeting autoimmune skin diseases such as cutaneous lupus erythematosus (CLE). …